A federal outside panel voted Thursday to loosen rules on seven peptides, including BPC-157 and TB-500. The vote was close. It is not final. The FDA has given no signal on whether it will move in step with the panel. The move came after weeks of public comment sessions. Wellness backers pressed strongly for wider access. RFK Jr. was among them. Critics say these compounds have weak safety evidence or help for most uses. The call could redefine how the agency handles a part of the wellness market that is moving at speed. Watchers are waiting to see if the agency takes up the plan. A spokesperson offered no firm timeline for a next step. Critics argue the change would open up access to substances some say help. Health groups warn that looser rules could weaken safeguards across a wide-open market. The committee vote only plants the seed for a shift, and the ultimate call rests with the federal agency.